Warning
This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.

4-FA

From PsychonautWiki Archive
Revision as of 19:59, 21 February 2015 by >Cocoanatta (Created page with "{{SubstanceBox/4-FA}} {{Stub}} '''4-Fluoroamphetamine''' ('''4-FA''') is a substituted amphetamine with stimulant, enactogenic and nootropic effects. It is rar...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
4-FA
Chemical Nomenclature
Common names 4-FA, 4-FMP, PAL-303, Flux
Substitutive name 4-Fluoroamphetamine, para-Fluoroamphetamine
Systematic name (RS)-1-(4-Fluorophenyl)-N-propan-2-amine
Class Membership
Psychoactive class Stimulant / Entactogen
Chemical class Amphetamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.



Oral
Dosage
Threshold 40 mg
Light 40 - 100 mg
Common 100 - 130 mg
Strong 130 - 150 mg
Heavy 150 mg +
Duration
Total 5 - 8 hours
Onset 45 - 75 minutes
Come up 30 - 75 minutes
Peak 2.5 - 3.5 hours
Offset 2 - 3 hours
After effects 6 - 12 hours









DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
Alcohol
GHB
GBL
Opioids
Cannabis
Caffeine
Ketamine
Methoxetamine
Psychedelics
Cocaine
DXM
PCP
25x-NBOMe
2C-T-x
5-MeO-xxT
DOx
Tramadol
aMT
MAOIs

This article is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

4-Fluoroamphetamine (4-FA) is a substituted amphetamine with stimulant, enactogenic and nootropic effects. It is rarely found on the streets but commonly sold as a grey area research chemical through online vendors.[1]

Chemistry

4-Fluoroamphetamine (2-FA) is a phenethylamine of the substituted amphetamine family. It contains a fluorine bound to C4 of the phenyl group.

Pharmacology

4-Fluoroamphetamines pharmacology differs based on the amount of substance consumed. When 100mgs or more is introduced 4-FA acts as releasing agent and reuptake inhibitor of dopamine, serotonin, and norepinephrine, producing euphoric, enactogenic effects similar to MDMA. When lower doses of >75mg are ingested it only acts on dopamine and norephinephrine, producing effects more similar to a functional stimulant. The mechanism of action of 4-FA effectively boosts the levels of the norepinephrine, dopamine, and serotonin [[neurotransmitters] in higher doses in the brain, by binding to, and partially blocking the transporter proteins that normally remove those monoamines from the synaptic cleft. This allows dopamine, norepinephrine and serotonin to accumulate within the brain, resulting in stimulating and euphoric effects.[2] [3] [4]

Studies demonstrate that 4-flourine amphetamine substitutions limit activity of the compound at the alpha-1 adrenergic receptor with an over 200-fold increased selectivity for A2 receptors over A1 receptors[5]. It has also been demonstrated that 4-substitution of a hydrogen with fluorine on the aromatic ring of norepinephrine produces a beta-adrenergic agonist with little alpha activity.[6] This has lead the online community to speculate that the milder uncomfortable cognitive and/or physical side effects and greater efficacy as a a nootropic associated with this substance are at least partially due to decreased activity at the alpha-1 adrenergic receptors resulting in significantly less norepinephrine reuptake inhibition.

Subjective effects

In comparison to other substituted amphetamines, 4-FA is particularly free of side effects such as nausea, high blood pressure, anxiety and an uncomfortable offset. Im low doses it is considered to be an extremely functional and effective nootropic for performing tasks general productivity of any sort. At higher dosages however, it becomes dysfunctional and recreational due to the intensity of its euphoria and stimulation.

The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely if ever occur all at once but heavier dosages will increase the chances and are more likely to induce a full range of effects.

Physical effects

Cognitive effects

Toxicity and harm potential

The toxicity and long term health effects of recreational 2-FMA use does not seem to have been studied in any scientific context and the exact toxic dosage is unknown. This is because 2-FMA is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 2-FMA suggests that there are no negative health effects attributed to simply trying this drug at low to moderate doses or using it very sparingly (but nothing can be completely guaranteed).

Tolerance and addiction potential

Tolerance develops rapidly with repeated usage, so periods of extended use require increasing doses of the drug in order to achieve the same effect. Addiction is a serious risk with heavy recreational use of any substituted amphetamine and compulsive redosing is extremely common.

Psychosis

Abuse of amphetamines at high dosages for prolonged periods of time can result in a stimulant psychosis that may present with a variety of symptoms (e.g., paranoia, hallucinations, delusions).[7] A Cochrane Collaboration review on treatment for amphetamine, dextroamphetamine, and methamphetamine abuse-induced psychosis states that about 5–15% of users fail to recover completely.[8][9] The same review asserts that, based upon at least one trial, antipsychotic medications effectively resolve the symptoms of acute amphetamine psychosis.[10] Psychosis very rarely arises from therapeutic use.[11][12]

2-FMA is currently a grey area compound within all parts of the world. This means that it is not known to be specifically illegal within any country but that people may still be charged for its possession under certain circumstances such as under analogue laws and with intent to sell or consume.

See also

References

  1. Isomeric fluoro-methoxy-phenylalkylamines: a new series of controlled-substance analogues (designer drugs). | http://www.ncbi.nlm.nih.gov/pubmed/15639609
  2. http://www.sciencedirect.com/science/article/pii/0028390875900994 | Comparison of 4-chloro-, 4-bromo-and 4-fluoroamphetamine in rats: drug levels in brain and effects on brain serotonin metabolism
  3. http://www.sciencedirect.com/science/article/pii/S0014299906013811
  4. http://www.sciencedirect.com/science/article/pii/S0014299906013811 | The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain
  5. 2-(Arylalkylamino)adenosin-5'-uronamides: a new class of highly selective adenosine A2 receptor ligands | http://pubs.acs.org/doi/abs/10.1021/jm00169a015
  6. Effect of fluorine substitution on the agonist specificity of norepinephrine | http://www.sciencemag.org/content/204/4398/1217.short
  7. Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
  8. Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
  9. Hofmann FG (1983). A Handbook on Drug and Alcohol Abuse: The Biomedical Aspects (2nd ed.). New York: Oxford University Press. p. 329. ISBN 9780195030570.
  10. Treatment for amphetamine psychosis | http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003026.pub3/abstract?systemMessage=Wiley+Online+Library+will+be+disrupted+Saturday%2C+15+March+from+10%3A00-12%3A00+GMT+%2806%3A00-08%3A00+EDT%29+for+essential+maintenance
  11. Stimulant Misuse: Strategies to Manage a Growing Problem | http://www.acha.org/prof_dev/ADHD_docs/ADHD_PDprogram_Article2.pdf
  12. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021303s026lbl.pdf